Tag: FRANKFURT:AGW
May 26, 2020
Pharmaceutical Companies Repurposing Drugs to Accelerate Growth
The drug development process can be incredibly costly, both in terms of the financial commitment required and the time necessary...
May 15, 2020
Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, is pleased to announce that it has submitted for ethics approval in...
May 6, 2020
Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia
Algernon Pharmaceuticals has received ethics approval for the planned Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil).
May 5, 2020
Algernon Amends Terms of Private Placement Offering of Special Warrants
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) has amended certain terms of its brokered private placement, being conducted...
May 1, 2020
Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants
Algernon Pharmaceuticals a clinical stage pharmaceutical development company, has entered into an agreement with Mackie Research Capital Corporation
April 30, 2020
Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) has received a No Objection Letter from Health Canada to proceed...
April 29, 2020